Skip to main content
Clinical Trials/NCT04203758
NCT04203758CompletedNot Applicable

High Fiber Rye Foods for Body Weight and Body Fat Reduction - The RyeWeight2 Study, a Randomized Controlled Trial.

Chalmers University of Technology1 site in 1 country255 target enrollmentStarted: January 20, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
255
Locations
1
Primary Endpoint
Investigate if there is a difference in body fat mass at week 12

Study Overview

Brief Summary

The overall aim of this study is to investigate whether a diet rich in rye fiber from wholegrain rye, compared to refined wheat, as part of a hypo-caloric diet leads to larger weight loss and lower body fat content after 12 weeks of intervention.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
30 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Men and women
  • Age 30-70 y
  • BMI 27-35 kg/m2
  • Hemoglobin ≥117g/l for women and for men ≥134g/l
  • Thyroid stimulating hormone (TSH) ≤4.30 mIU/L
  • Low density lipoprotein (LDL) cholesterol ≤5.30 mmol/L
  • Triglycerides ≤2.60 mmol/L
  • Signed informed consent

Exclusion Criteria

  • Blood donation or participation in a clinical study with blood sampling within 30 days prior to screening visit and throughout the study
  • Unable to satisfactorily complete the 3-day weighted food record between screening visits.
  • Unable to lose ≥0.5 kg during the run-in period for men and women not having menstruation during the run-in period
  • Increased body weight, despite reported adherence to dietary intake for women with menstruation during the run-in period.
  • Using nicotine products on a daily basis (incl. chewing gum, patches, snus etc.)
  • Using e-cigarettes (regardless of nicotine content)
  • Following any weight reduction program or having followed one during the last 6 months prior to visit
  • Diastolic blood pressure 105 mmHg or more at visit 1
  • Systolic blood pressure 160 mmHg or more at visit 1
  • History of stomach or gastrointestinal conditions (Inflammatory bowel disease, Crohn's disease, malabsorption, colostomy, bowel resection, gastric bypass surgery etc.)
  • More than 10 hours physical activity per week
  • History of heart failure or heart attack within 1 year prior to screening
  • Having type I diabetes
  • Receiving pharmacological treatment for type II diabetes (treatments based on life style interventions are acceptable, as long as they are compatible with the study protocol)
  • Previous gastrointestinal surgery, with the exception of minor surgeries such removal of appendix or gall bladder at least 6 months prior to screening.
  • Thyroid disorder
  • History of eating disorder
  • History of drug or alcohol abuse
  • Stroke or transient ischemic attack (TIA) within 1 year prior to screening
  • Consumption of drugs aimed at weight management or drugs affecting body weight to a degree that is considered unsuitable for study participation by responsible physician.
  • Pregnant, lactation or planning a pregnancy within the timeframe of the study. Pregnancy must have ended at least 6 months prior to screening, and lactation must have ended at least 1 month prior to screening.
  • Food allergies or intolerances preventing consumption of any products included in the study
  • Strict vegetarian (participants must be able to consume the standardized meals used for appetite assessment)
  • Unable to sufficiently understand written and spoken Swedish to provide written consent and understand information and instructions from the study personal.
  • Lack of suitability for participation in the study, for any reason, as judged by the medical doctor or PI.

Outcomes

Primary Outcomes

Investigate if there is a difference in body fat mass at week 12

Time Frame: 12 weeks

Measured by dual energy x-ray absorptiometry

Investigate if there is a difference in body weight at week 12

Time Frame: 12 weeks

Measured on a scale

Secondary Outcomes

  • Investigate if lean body mass differs between intervention groups after 6 and 12 weeks of intervention(6 weeks and 12 weeks)
  • Investigate if fasting serum insulin differ between groups(6 weeks and 12 weeks)
  • Investigate if hip circumference differ between intervention groups(6 weeks and 12 weeks)
  • Investigate if fasting plasma total cholesterol differ between groups(6 weeks and 12 weeks)
  • Investigate if fasting plasma glucose differ between groups(6 weeks and 12 weeks)
  • Investigate if gut microbiota composition is affected by the intervention(6 weeks and 12 weeks)
  • Investigate if waist circumference differ between intervention(6 weeks and 12 weeks)
  • Investigate if there are differences in subjective appetite ratings(0 weeks, 6 weeks and 12 weeks.)
  • Investigate if differences in primary endpoints (body weight) are apparent at week 6(6 weeks)
  • Investigate if differences in primary endpoints (fat mass) are apparent at week 6(6 weeks)
  • Investigate if fasting plasma triglycerides differ between groups(6 weeks and 12 weeks)
  • Investigate if fasting plasma high-density lipoprotein cholesterol differ between groups(6 weeks and 12 weeks)
  • Investigate if C-reactive protein differ between groups(6 weeks and 12 weeks)
  • Investigate if abdominal fat mass differs between intervention groups after 6 and 12 weeks of intervention(6 weeks and 12 weeks)
  • Investigate if fasting plasma low-density lipoprotein cholesterol differ between groups(6 weeks and 12 weeks)
  • Investigate if sagittal height differ between intervention groups(6 weeks and 12 weeks)

Investigators

Sponsor
Chalmers University of Technology
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Rikard Landberg

Professor

Chalmers University of Technology

Study Sites (1)

Loading locations...

Similar Trials

High Fiber Rye Foods for Body Weight and... | Clinical Trial